Bridging the gap between
technology and neuroscience.
Approximately 10% of children worldwide are diagnosed with attention deficit/hyperactivity disorder (ADHD), which manifests as deficiencies being present in daily life activities that require cognitive control – attention, working memory and goal-management skills. Given the personal impact, as well as the large socioeconomic and health-care burden posed by ADHD, the development of effective and scalable therapeutics for impaired children has immense practical relevance.
At Neuroscape, we are driven to create and evaluate sophisticated new approaches to properly characterize the challenges faces by children with ADHD, as well as harness their brain’s inherent plasticity with closed-loop systems being developed in our Technology Program so as to remediate deficient cognitive control abilities and improve their quality of life.